Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2005

View Archived Issues

Millennium updates pipeline progress

Locteron begins phase I study for chronic hepatitis C

Satraplatin begins phase II study in metastatic breast cancer

Tm Bioscience develops upper respiratory viral panel

GTC Biotherapeutics and LEO Pharma enter agreement for ATryn

Positive outcome for BEMA-fentanyl in comparative pharmacokinetics study

Alnylam seeks clearance for phase I study of ALN-RSV01 for RSV

Antiviral FluCide-I begins preclinical studies

DOR BioPharma to acquire Gastrotech Pharma

NF-676: novel and potent use-dependent blocker of RyR1

SL-650155 reveals effects of serotonin in models of amnesia

ACTOplus met available in U.S. for type 2 diabetes

Novel agents for the treatment of neurological disorders disclosed in recent patents

Recent patents report compounds with potential use in the treatment of respiratory disorders

New treatments for cancer covered in recent patents

In vitro effects of anti-TNF-alpha agents on apoptosis and cytotoxicity

AT-001 reported effective in the treatment of rheumatoid arthritis

AmPrbetaCD: a novel anthrax lethal toxin inhibitor

Update on the therapeutic benefits of quetiapine in psychological disorders

Acadia presents a new potent, orally available, isoform-selective RARbeta2 agonist

Phase I data on tgAAC94 in inflammatory arthritis

Clinical evidence confirms transdermal selegiline is safe in patients with major depression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...